Michel Detheux - 31 Dec 2022 Form 5 Insider Report for iTeos Therapeutics, Inc. (ITOS)

Role
Chief Executive Officer
Signature
/s/ Adi Osovsky, as Attorney-in-Fact
Issuer symbol
ITOS
Transactions as of
31 Dec 2022
Net transactions value
$0
Form type
5
Filing time
10 Mar 2023, 18:50:52 UTC
Previous filing
19 Apr 2022
Next filing
10 Mar 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ITOS Stock Option (Right to Buy) Gift $0 -264,375 -75% $0.000000 88,125 15 Apr 2022 Common Stock 264,375 $36.21 Direct F1, F2
transaction ITOS Stock Option (Right to Buy) Gift $0 +264,375 $0.000000 264,375 15 Apr 2022 Common Stock 264,375 $36.21 By MG3A F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reporting person transferred these stock options to MG3A, a Belgian partnership of which the reporting person is the manager and the reporting person's spouse is the successor manager.
F2 This stock option vests over four years, with 25% vesting on March 11, 2023 and thereafter in equal monthly installments over the next 36 months, subject to the reporting person's continued service to the Issuer.